XML 18 R9.htm IDEA: XBRL DOCUMENT v3.23.1
NET SALES
9 Months Ended
Mar. 31, 2023
Equity [Abstract]  
NET SALES

NOTE 3. NET SALES

 

The following table presents the disaggregation of net sales by revenue recognition model (in thousands):

 

                    
   Three Months Ended
March 31,
   Nine Months Ended
March 31,
 
   2023   2022   2023   2022 
Net Sales:                    
Over-time revenue recognition   $970   $549   $2,361   $859 
Point-in-time revenue recognition    12,109    8,716    33,087    28,567 
Total net sales   $13,079   $9,265   $35,448   $29,426 

 

The timing of revenue recognition, billings, and cash collections results in billed accounts receivables, unbilled receivables (presented as deferred costs on our condensed consolidated balance sheets) and customer advances and deposits (presented as deferred revenue on our condensed consolidated balance sheets), where applicable. Amounts are generally billed as work progresses in accordance with agreed upon milestones. The over-time revenue recognition model consists of non-recurring engineering (“NRE”) and prototype services and typically relates to NRE services related to the evaluation, design or customization of a medical device and is typically recognized over time utilizing an input measure of progress based on costs incurred compared to the estimated total costs upon completion. During the three and nine months ended March 31, 2023, we recorded $405,000 and $956,000, respectively, of revenue that had been included in deferred revenue in the prior year. During the three and nine months ended March 31, 2022, we did not record any revenue that had been included in deferred revenue in the prior year. The revenue recognized from the contract liabilities consisted of satisfying our performance obligations during the normal course of business. Our entire deferred revenue balance of $57,000 at March 31, 2023, is currently expected to be recognized in the next 12-month period.

The following tables summarize our contract assets and liability balances (in thousands):

                    
  

As of and for the

Three Months Ended
March 31,

  

As of and for the

Nine Months Ended
March 31,

 
   2023   2022   2023   2022 
Contract assets beginning balance   $877   $424   $710   $193 
     Expenses incurred during the year    362   $371   $1,108   $732 
     Amounts reclassified to cost of sales    (935)   (445)   (1,497)   (556)
     Amounts allocated to discounts for standalone selling price    (25)   (9)   (42)   (28)
Contract assets ending balance   $279   $341   $279   $341 

 

                    
  

As of and for the

Three Months Ended
March 31,

  

As of and for the

Nine Months Ended
March 31,

 
   2023   2022   2023   2022 
Contract liabilities beginning balance   $851   $584   $1,013   $150 
     Payments received from customers    41   $861   $741   $1,393 
     Amounts reclassified to revenue    (835)   (549)   (1,697)   (647)
Contract liabilities ending balance   $57   $896   $57   $896